NEIL L SPECTOR, MD
Osteopathic Medicine at Roxboro St, Durham, NC
License number
North Carolina 99-01326
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
4101 N Roxboro St, Durham, NC 27704
Phone
(919) 684-8111
Professional information
Dr. Neil L Spector, Durham NC - MD (Doctor of Medicine)
Specialties:
Hematology, Medical Oncology, Oncology
Address:
4101 N Roxboro St, Durham 27704
(919) 684-8111 (Phone)
2301 Erwin Rd STE 601, Durham 27705
(919) 681-4699 (Phone), (919) 684-5653 (Fax)
(919) 684-8111 (Phone)
2301 Erwin Rd STE 601, Durham 27705
(919) 681-4699 (Phone), (919) 684-5653 (Fax)
Certifications:
Hematology, 1988, Internal Medicine, 1986, Medical Oncology, 1989
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
4101 N Roxboro St, Durham 27704
2301 Erwin Rd STE 601, Durham 27705
Duke Health Raleigh Hospital
3400 Wake Forest Rd, Raleigh 27609
Duke University Hospital
2301 Erwin Rd, Durham 27710
Durham Regional Hospital
3643 North Roxboro Rd, Durham 27704
2301 Erwin Rd STE 601, Durham 27705
Duke Health Raleigh Hospital
3400 Wake Forest Rd, Raleigh 27609
Duke University Hospital
2301 Erwin Rd, Durham 27710
Durham Regional Hospital
3643 North Roxboro Rd, Durham 27704
Education:
Medical School
University of Medicine And Dentistry of New Jersey / Newark
Graduated: 1982
Parkland Hosp/Sw Med Sch
Massachusetts General Hospital
University of Medicine And Dentistry of New Jersey / Newark
Graduated: 1982
Parkland Hosp/Sw Med Sch
Massachusetts General Hospital
Neil Spector, Durham NC
Specialties:
Internal Medicine, Hematology, Medical Oncology, Hematology & Oncology
Work:
Durham Va Medical Center
508 Fulton St, Durham, NC 27705 Private Diagnostic Clinic
1000 Trent Dr, Durham, NC 27710
508 Fulton St, Durham, NC 27705 Private Diagnostic Clinic
1000 Trent Dr, Durham, NC 27710
Education:
UMDNJ (1982)
Cancer Treatment Method
US Patent:
2010006, Mar 11, 2010
Filed:
Jun 1, 2005
Appl. No.:
11/569877
Inventors:
Mark S. Berger - Merion Station PA, US
Tona Morgan Gilmer - Durham NC, US
Arundathy Nirmalini Pandite - Durham NC, US
David Rusnak - Durham NC, US
Neil L. Spector - Durham NC, US
Iman El-Hariry - Greenford, GB
Tona Morgan Gilmer - Durham NC, US
Arundathy Nirmalini Pandite - Durham NC, US
David Rusnak - Durham NC, US
Neil L. Spector - Durham NC, US
Iman El-Hariry - Greenford, GB
International Classification:
A61K 31/517, A61P 35/00
US Classification:
51426624
Abstract:
The present invention relates to a method of treating cancer in a mammal by administration of 4-quinazolinamines and pharmaceutical compositions containing the same. In particular, the method relates to a methods of treating cancers which are mediated by the tyrosine kinases EGFR and/or erbB2 by administration of N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine and salts and solvates thereof.
Treatment Of Cancers Expressing P95 Erbb2
US Patent:
7829297, Nov 9, 2010
Filed:
Feb 5, 2009
Appl. No.:
12/366457
Inventors:
Neil Lee Spector - Durham NC, US
Wenle Xia - Durham NC, US
Wenle Xia - Durham NC, US
Assignee:
GlaxoSmithKline LLC - Philadelphia PA
International Classification:
A61K 38/00, C07K 2/00, C07K 4/00, C07K 5/00, C07K 7/00, C07K 14/00, C07K 16/00, C07K 17/00, A01N 37/18
US Classification:
435 71, 435 4, 514 2, 530300, 530350
Abstract:
The truncated ErbB2 receptor (p95) is shown to differ from the full-length ErbB2 receptor in its association with other ErbB receptors. The truncated receptor preferentially associated with ErbB3, whereas full length ErbB2 heterodimerizes with either EGFR or ErbB3. Consistent with p95heterodimerization with ErbB3, it is shown that heregulin (an ErbB3 ligand) stimulates p95phosphorylation in breast cancer cell lines. Described herein are methods of identifying patients suitable for treatment with a p95inhibitor, and methods of treating such patients.
Cancer Treatment Method Comprising Administering An Erb-Family Inhibitor And A Raf And/Or Ras Inhibitor
US Patent:
2005017, Aug 11, 2005
Filed:
Apr 8, 2003
Appl. No.:
10/510542
Inventors:
Neil Spector - Durham NC, US
Wenle Xia - Durham NC, US
Wenle Xia - Durham NC, US
International Classification:
A61K031/519
US Classification:
514264110
Abstract:
The present invention relates to a method of treating cancer in a mammal and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering an erb family inhibitor and a Raf and/or ras inhibitor to a mammal suffering from a cancer.
Treatment Of Cancers Expressing P95 Erbb2
US Patent:
2011002, Jan 27, 2011
Filed:
Sep 30, 2010
Appl. No.:
12/894236
Inventors:
Neil Lee Spector - Durham NC, US
Wenle Xia - Durham NC, US
Wenle Xia - Durham NC, US
International Classification:
A61K 39/395, A61K 31/517, A61P 35/00
US Classification:
4241331, 51426624
Abstract:
The truncated ErbB2 receptor (p95) is shown to differ from the full-length ErbB2 receptor in its association with other ErbB receptors. The truncated receptor preferentially associated with ErbB3, whereas full length ErbB2 heterodimerizes with either EGFR or ErbB3. Consistent with p95heterodimerization with ErbB3, it is shown that heregulin (an ErbB3 ligand) stimulates p95phosphorylation in breast cancer cell lines. Described herein are methods of identifying patients suitable for treatment with a p95inhibitor, and methods of treating such patients.
Treatment Of Cancers Expressing P95 Erbb2
US Patent:
2006020, Sep 14, 2006
Filed:
Aug 2, 2004
Appl. No.:
10/567012
Inventors:
Neil Spector - Durham NC, US
Wenle Xia - Durham NC, US
Wenle Xia - Durham NC, US
International Classification:
C12Q 1/68, G01N 33/574
US Classification:
435006000, 435007230
Abstract:
The truncated ErbB2 receptor (p95) is shown to differ from the full-length ErbB2 receptor in its association with other ErbB receptors. The truncated receptor preferentially associated with ErbB3, whereas full length ErbB2 heterodimerizes with either EGFR or ErbB3. Consistent with p95heterodimerization with ErbB3, it is shown that heregulin (an ErbB3 ligand) stimulates p95phosphorylation in breast cancer cell lines. Described herein are methods of identifying patients suitable for treatment with a p95inhibitor, and methods of treating such patients.
Biomarkers In Cancer
US Patent:
2007005, Mar 15, 2007
Filed:
Aug 10, 2004
Appl. No.:
10/568251
Inventors:
Sarah Bacus - Hinsdale IL, US
Neil Spector - Durham NC, US
Neil Spector - Durham NC, US
Assignee:
SMITHKLINE BEECHAM CORPORATION - Philadelphia PA
International Classification:
G01N 33/574
US Classification:
435007230
Abstract:
Biomarkers may be used in the treatment of cancer, and as an aid in clinical decision making regarding which anti-cancer therapy to use in a particular patient. Described herein are methods of assessing whether a subject with a solid tumor is suitable for treatment with a dual EGFR/erbB2 tyrosine kinase inhibitor, by assessing the relative localization of pERK or pAKT in tumor cells, and/or assessing pre-treatment tumor cell levels of ErbB2.
Predictive Biomarkers In Cancer Therapy
US Patent:
7794960, Sep 14, 2010
Filed:
May 12, 2005
Appl. No.:
11/569980
Inventors:
Neil Lee Spector - Durham NC, US
Albert Man - La Jolla CA, US
Albert Man - La Jolla CA, US
Assignee:
GlaxoSmithKline LLC - Philadelphia PA
International Classification:
G01N 33/53
US Classification:
435 723, 435 6, 436501, 436518
Abstract:
The use of various biomarkers to assess a subject's suitability for treatment with a EGFR/ErbB2 kinase inhibitor for a solid tumor are described. The biomarkers include TGFalpha, pS6, IGF-1R and levels of apoptosis occurring in tumor tissue.
Predictive Markers In Cancer Therapy
US Patent:
2006009, May 4, 2006
Filed:
Apr 24, 2003
Appl. No.:
10/529922
Inventors:
Sarah Bacus - Tuscon AZ, US
Myra Herrle - Durham NC, US
L. Kirk - Durham NC, US
Neil Spector - Durham NC, US
Michael Stocum - Durham NC, US
Wenle Xia - Durham NC, US
Myra Herrle - Durham NC, US
L. Kirk - Durham NC, US
Neil Spector - Durham NC, US
Michael Stocum - Durham NC, US
Wenle Xia - Durham NC, US
International Classification:
G01N 33/574, A61K 31/52
US Classification:
435007230, 514263100
Abstract:
Molecular markers useful in medicine response tests are provided, as an aid in determining whether an individual subject s tumor is responding to treatment with EGF and/or erbB2 inhibitors. Markers include phosphorylated ERK protein